On Thursday, members of both the U.S. House of Representatives and the U.S. Senate introduced legislation that targets efforts that have limited competition, which keeps the price of prescription drugs high.

The high cost of insulin to treat diabetes would be drastically reduced under legislation the U.S. House of Representatives passed on March 31, in a rare example of drug price reform gaining traction in Congress.

Martin Shkreli received his second lifetime ban from the pharmaceutical industry. One month after U.S. District Court Judge Denise Cotes banned the “Pharma Bro” from future involvement in the industry, a second judge handed down a similar order and ordered him to pay a $1.39 million fine.

President Joe Biden called for the U.S. Senate to approve his Build Back Better legislation to reduce the costs of prescription drugs provided through Medicare and cap out-of-pocket drug costs for seniors.

A U.S. judge on January 14 barred Martin Shkreli from the pharmaceutical industry for life and ordered him to pay $64.6 million after he famously raised the price of the drug Daraprim and fought to block generic competitors.

The U.S. Federal Trade Commission and seven states on December 7 settled claims accusing Vyera Pharmaceuticals of trying to block generic versions of the company’s life-saving drug Daraprim, but are preparing for a Dec. 14 trial against accused mastermind Martin Shkreli.

pharmaceuticals

Democratic Party lawmakers holding up proposed drug pricing reforms are among the largest beneficiaries of the pharmaceutical industry’s push to stave off price cuts, a Reuters analysis of public lobbying and campaign data shows.

Immunology is one of the more complicated areas of the life sciences, and recent studies on the long-term efficacy of the mRNA vaccines against Covid-19 are prime examples of just how complicated it can be.

The U.S. Food and Drug Administration approved Biogen’s aducanumab, the first drug to target an underlying cause of Alzheimer’s disease. The drug, to be sold under the brand Aduhelm, is the first new approval of an Alzheimer’s drug since 2003 and the only treatment designed to slow progression of the mind-robbing disease.

U.S. lawmakers from both parties and both houses of Congress introduced eight antitrust bills aimed at tackling the problem of high and rising drug prices, including bills to stop brand name drug companies from paying generic firms to stay off the market.